By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alza Corp. et al. v. Impax Laboratories, Inc. et al.
1:11-cv-00395; filed May 5, 2011 in the District Court of Delaware
• Plaintiffs: Alza Corp.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.
• Defendants: Impax Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.
Infringement of U.S. Patent No. 6,930,129 ("Methods and Devices for Providing Prolonged Drug Therapy," issued August 16, 2005) following a Paragraph IV certification as part of Impax's amendment of its ANDA (adding additional dosage forms) to manufacture a generic version of Alza's Concerta® (methylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Flamel Technologies S.A. v. Lupin Ltd. et al.
1:11-cv-00826; filed May 4, 2011 in the District Court of the District of Columbia
• Plaintiff: Flamel Technologies S.A.
• Defendants: Lupin Ltd.; Lupin Pharmaceuticals, Inc.
Infringement of U.S. Patent No. 6,022,562 ("Medicinal and/or Nutritional Microcapsules for Oral Administration," issued February 8, 2000) following a paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of GSK's Coreg® CR (carvedilol, used to treat congestive heart failure). View the complaint here.
Novartis AG et al. v. Kappos
1:11-cv-00821; filed May 3, 2011 in the District Court of the District of Columbia
• Plaintiffs: Novartis AG; Novartis Corp.
• Defendant: David J. Kappos
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent Nos. 7,081,532 ("N-phenyl-2-pyrimidine-amine Derivatives," issued July 25, 2006), 7,097,827 ("Devices, Compositions and Methods for the Pulmonary Delivery of Aerosolized Medicaments," issued August 29, 2006), 7,253,257 ("Human Metabotropic Glutamate Receptor Subtype mGluR7b," issued August 7, 2007), 7,323,451 ("Crystalline and Amorphous Forms of Beta-L-2′-deoxythymidine," issued January 29, 2008), 7,442,388 ("Phospholipid-based Powders for Drug Delivery," issued October 28, 2008), 7,516,741 ("Aerosolization Apparatus with Feedback Mechanism," issued April 14, 2009), 7,687,637 ("5-phenylthiazole Derivatives and Use as Pi3 Kkinase Inhibitors," issued March 30, 2010), 7,696,216 ("Aryl-quinazoline/aryl-2-amino-phenyl Methanone Derivatives," issued April 13, 2010), and 7,776,851 ("Use of Neurokinin Antagonists in the Treatment of Urinary Incontinence," issued August 17, 2010). View the complaint here.
Takeda Pharmaceutical Co. et al. v. Mylan Inc. et al.
3:11-cv-02506; filed May 2, 2011 in the District Court of New Jersey
• Plaintiffs: Takeda Pharmaceutical Co.; Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceuticals LLC; Takeda Pharmaceuticals America, Inc.; Ethypharm, S.A.
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent Nos. 5,464,632 ("Rapidly Disintegratable Multiparticular Tablet," issued December 7, 1995) and 6,328,994 ("Orally Disintegrable Tablets," issued December 11, 2001) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of plaintiffs' Prevacid® SoluTab (lansoprazole delayed release orally disintegrating tablets, used to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, and pathological hypersecretory conditions, including Zollinger-Ellison syndrome). View the complaint here.
Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.
2:11-cv-02523; filed May 2, 2011 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,895,059 ("Sensitive Drug Distribution System and Method" issued February 22, 2011) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Jazz's Xyrem® (sodium oxybate, used to treat narcolepsy). View the complaint here.
Comments